Search Results
287 Results Found for “glycemic control”
In response to the increasing prevalence of obesity, the consumption of high-calorie and high-sugar foods and an unprecedented aging population, type 2 diabetes (T2D) continues to rise globally. The International Diabetes Federation reported that 589 million individuals aged 20 to 79 years had ...
Topline data from the TRIUMPH-2 and TRIUMPH-3 trials show substantial weight loss, improved glycemic control, and favorable changes in cardiometabolic risk markers with the investigational triple hormone receptor agonist in adults with obesity and type 2 diabetes or established cardiovascular disease.
Type 2 diabetes (T2D) is a progressive metabolic condition associated with obesity, cardiovascular disease and substantial morbidity and mortality.1 Despite the availability of multiple glucose-lowering therapies, a significant proportion of individuals with T2D fail to achieve recommended glycemic targets, ...
At ECE 2026, Evelien Gevers discussed data showing DCCR reduced hyperphagia in Prader–Willi syndrome and remained generally safe in patients with pre-diabetes or diabetes, supporting broader clinical confidence and access.
Peripheral neuropathy is a common and clinically heterogeneous condition resulting from damage to the peripheral nervous system, affecting sensory, motor and autonomic fibers.1 Its diagnostic complexity stems from a broad spectrum of etiologies, including metabolic, autoimmune, infectious, toxic, neoplastic and ...
The FDA has granted accelerated approval to teplizumab-mzwv to delay the decline in endogenous insulin production in children aged 8–17 years recently diagnosed with stage 3 type 1 diabetes (T1D).1 The approval marks the first disease-modifying treatment option for this population.
Dr Laurence Dobbie discusses a new European consensus statement highlighting the nutritional, functional and psychological considerations needed to support safe, effective and equitable use of incretin-based therapies in obesity management.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and GLP-1RA-based therapies are currently considered to be one of the most attractive classes of medications for managing type 2 diabetes (T2D) because of their impressive weight loss properties, glycated haemoglobin (HbA1c) ...
New data presented at the Advanced Technologies & Treatments for Diabetes 2026 highlight a shift in diabetes care beyond glucose control alone. Emerging evidence supports the growing role of incretin-based therapies such as semaglutide, alongside advances in continuous glucose monitoring systems including Dexcom G7 and Freestyle Libre 3. Together, these innovations demonstrate meaningful improvements in glycemic outcomes, cardiometabolic risk, and patient behaviors, signaling a move toward more personalized, integrated approaches to diabetes management across both type 1 and type 2 diabetes.
The past century has witnessed substantial evolution in the assessment and management of type 1 diabetes (T1D), paralleling advances in our understanding of the condition and in innovation in technology. Since the ground-breaking discovery of insulin in the 1920s, T1...
Insulin resistance (IR), a hallmark of various metabolic disorders, represents a diminished responsiveness of target tissues to the actions of insulin, resulting in impaired glucose uptake, dyslipidaemia and endothelial dysfunction.1,2 Worldwide, the prevalence of IR among adults ranges from 15.5% to 46.5%.3–5 ...
ObesityWeek® 2025 highlighted obesity as a chronic, multi-system disease that links cardiovascular, renal, and metabolic health. New data from clinical trials showcased therapies improving weight, blood pressure, and inflammation, signalling a shift toward integrated care where obesity management becomes central to cardiovascular-kidney-metabolic health.
Gestational diabetes (GD) is a heterogeneous disorder that arises when pancreatic insulin secretion fails to compensate for the insulin resistance of pregnancy. A disbalance in either component, insufficient secretion or excessive resistance, can lead to GD and reflects its variable ...
Dr Lindsey Gaston is a paediatric endocrinologist and physician-scientist at Boston Children’s Hospital, where she also completed her residency and fellowship in paediatric endocrinology. Her research focuses on understanding the mechanisms of prolonged adrenal suppression following long-term glucocorticoid therapy, ...
Prof Mak, a leading clinician-scientist in hepatology, discusses her inspirations, groundbreaking research on liver diseases, and commitment to patient-centered care. She reflects on milestones in her career and shares insights into emerging therapies and trends transforming the field.
Very few trials in the history of medical science have altered the treatment landscape as profoundly as the UK Prospective Diabetes Study (UKPDS). Even 44 years after its inception, the trial and post-study follow-up findings continue to fascinate and enlighten the ...
Dry eye disease (DED) is known as dry eye syndrome (DES) or keratoconjunctivitis sicca. According to the Tear Film and Ocular Surface Society’s Dry Eye Workshop II (TFOS DEWS II), it constitutes a multifactorial disease of the ocular surface, ...
Highlights Enhanced external counterpulsation (EECP) is evaluated for glycaemic control in type 2 diabetes. Glycated haemoglobin reduction immediately after EECP therapy conclusion, after 2–4 weeks and after 7–12 weeks was -0.70%, 1.04% and 0.98%, respectively. EECP is associated with a significant lowering of blood pressure. ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
